Sanofi-Aventis Grabs Start-up BiPar, Reels In Promising PARP Inhibitor For Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
All-cash deal could be worth up to $500 million in upfront and milestone payments.
You may also be interested in...
People In The News: Tracking The Latest Industry Personnel Moves
Former CMS Administrator Don Berwick joins think tank Center for American Progress as senior fellow. Elan announces the upcoming departure of CEO Kelly Martin. More personnel announcements in this month’s column.
Reenergizing R&D: Sanofi Stirs The Pot, But Does It Have The Recipe?
Sanofi-Aventis SA spent the past year culling drug candidates and reorganizing its research group in an attempt to shape up a shoddy pipeline. Now, though the company is in the midst of a hostile bid to acquire the biotech Genzyme – an acquisition attempt spurred by the fact the French drug maker doesn't have enough new drugs to make up for the ones it is losing to generics – management maintains that the reorganized research group is on track to become one of the most productive in the industry.
Reenergizing R&D: Sanofi Stirs The Pot, But Does It Have The Recipe?
Sanofi-Aventis SA spent the past year culling drug candidates and reorganizing its research group in an attempt to shape up a shoddy pipeline. Now, though the company is in the midst of a hostile bid to acquire the biotech Genzyme – an acquisition attempt spurred by the fact the French drug maker doesn't have enough new drugs to make up for the ones it is losing to generics – management maintains that the reorganized research group is on track to become one of the most productive in the industry.